期刊
CLINICS IN DERMATOLOGY
卷 30, 期 1, 页码 3-16出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.clindermatol.2011.03.005
关键词
-
类别
资金
- European Community [1-HEALTH-F2-2008-200515]
- Swiss National Foundation for Scientific Research [31003A-121966, 31003A-09811]
- Swiss Foundation for Research in Muscle Diseases
- Italian Ministry of Health
- Swiss National Science Foundation (SNF) [31003A_121966] Funding Source: Swiss National Science Foundation (SNF)
Bullous pemphigoid (BP) constitutes the most frequent autoimmune subepidermal blistering disease. It is associated with autoantibodies directed against the BP antigens 180 (BP180, BPAG2) and BP230 (BPAG1-e). The pathogenicity of anti-BP180 antibodies has been convincingly demonstrated in animal models. The clinical features of BP are extremely polymorphous. The diagnosis of BP critically relies on immunopathologic findings. The recent development of novel enzyme-linked immunosorbent assays has allowed the detection of circulating autoantibodies with relatively high sensitivity and specificity. Although potent topical steroids have emerged in the past decade as first-line treatment of BP, management of the disease may be challenging. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据